Cargando…

SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab

Detalles Bibliográficos
Autores principales:	Stiasny, Karin, Weseslindtner, Lukas, Heinzel, Andreas, Camp, Jeremy V., Oberbauer, Rainer, Reindl-Schwaighofer, Roman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Health Archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790897/ https://www.ncbi.nlm.nih.gov/pubmed/36578452 http://dx.doi.org/10.3389/ti.2022.10906

Ejemplares similares

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
por: Dichtl, Stefanie, et al.
Publicado: (2022)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

Monitoring of Sotrovimab-Levels as Pre-Exposure Prophylaxis in Kidney Transplant Recipients Not Responding to SARS-CoV-2 Vaccines
por: Aschauer, Constantin, et al.
Publicado: (2023)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab
por: Fujita, Shigeru, et al.
Publicado: (2022)

Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)

Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections
por: Medits, Iris, et al.
Publicado: (2022)

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
por: Totschnig, David, et al.
Publicado: (2022)

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases
por: Otiniano, Armelle, et al.
Publicado: (2022)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022)

Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
por: Miyashita, Naoyuki, et al.
Publicado: (2023)

Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients
por: Gruber, Cesare Ernesto Maria, et al.
Publicado: (2023)

Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment
por: Vellas, Camille, et al.
Publicado: (2022)

(653) Tixagevimab and Cilgavimab Reduced the Likelihood of Covid after Heart Transplant in the Age of Omicron
por: Lee, R., et al.
Publicado: (2023)

Tixagevimab/ Cilgavimab Outcomes Among Patients with Immunodeficiency
por: Sullivan, Juliana
Publicado: (2023)

Young Adult Perspectives on Sex, Dating, and PrEP Use During the Pandemic and Improving the Future of PrEP Care
por: Camp, Christina E., et al.
Publicado: (2023)

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

The importance of PrEP persistence in preventing HIV infections on PrEP
por: Spinelli, Matthew A, et al.
Publicado: (2020)

Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023
por: Yang, Jinyoung, et al.
Publicado: (2023)

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir
por: Martin-Blondel, Guillaume, et al.
Publicado: (2023)

“PrEP”ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women
por: Pasipanodya, Elizabeth C., et al.
Publicado: (2021)

Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5
por: Diem, Gabriel, et al.
Publicado: (2023)

Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase
por: Aggarwal, Neil R., et al.
Publicado: (2023)

PrEP-RN: Clinical Considerations and Protocols for Nurse-Led PrEP
por: O'Byrne, Patrick, et al.
Publicado: (2019)

1287. PrEP-Engaged or PrEP Curious?: A Characterization and Comparison of Initial PrEP Appointment Attenders vs. Nonattenders
por: Kahal, Deborah A, et al.
Publicado: (2019)

Predictors of PrEP awareness, PrEP discussion and interest in long‐acting injectable PrEP among Filipina transfeminine adults
por: Restar, Arjee Javellana, et al.
Publicado: (2023)

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
por: Stuver, Robert, et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
por: Tuan, Jessica J., et al.
Publicado: (2023)

471. In-Depth Characterization of SARS-CoV-2 Variants Causing Breakthrough COVID-19 Among Hospitalized Immunocompromised (IC) Patients with or without Prior Exposure to Tixagevimab-Cilgavimab (T/C) Pre-Exposure Prophylaxis (PrEP)
por: Haidar, Ghady, et al.
Publicado: (2023)

Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
por: Karaba, Andrew H., et al.
Publicado: (2023)

Slow Uptake of PrEP: Behavioral Predictors and the Influence of Price on PrEP Uptake Among MSM with a High Interest in PrEP
por: van Dijk, Mart, et al.
Publicado: (2021)

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
por: Harman, Katie, et al.
Publicado: (2023)

Efficiency in PrEP Delivery: Estimating the Annual Costs of Oral PrEP in Zimbabwe
por: Mangenah, Collin, et al.
Publicado: (2021)

PrEP Indications and PrEP Knowledge, Access, and Interest Among Individuals With HCV
por: Hill, Kristi C, et al.
Publicado: (2022)

Complex PrEP: the factors requiring consultant-led review of PrEP users
por: Tittle, Victoria, et al.
Publicado: (2022)

“You can’t have a PrEP program without a PrEP Coordinator”: Implementation of a PrEP panel management intervention
por: Saberi, Parya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1a7oht9gtoa1tjqv2122s7lf51